Balancing innate immunity and inflammatory state via modulation of neutrophil function: A novel strategy to fight sepsis

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Fang, Haoshu ^a   Jiang, Wei ^a   Cheng, Jin ^a   Lu, Yan ^a   Liu, Anding ^b   Kan, Lixin ^a,c   Dahmen, Uta ^d  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c NORTHWESTERN UNIVERSITY   (United States)

^d JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; LIPOPOLYSACCHARIDE BINDING PROTEIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; ACUTE PHASE PROTEIN; CARRIER PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE-BINDING PROTEIN; MEMBRANE PROTEIN; TLR4 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

BACTERIAL CLEARANCE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL WALL; HOST RESISTANCE; HUMAN; INNATE IMMUNITY; NEUTROPHIL; NONHUMAN; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THERAPY EFFECT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MOUSE; PATHOLOGY; PHAGOCYTOSIS;

ACUTE-PHASE PROTEINS; ANIMALS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY, INNATE; MEMBRANE GLYCOPROTEINS; MICE; NEUTROPHILS; NF-KAPPA B; PHAGOCYTOSIS; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84954555383     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/187048     Document Type: Review

References (56)

1. R. S. Hotchkiss and I. E. Karl, "The pathophysiology and treatment of sepsis, "The New England Journal of Medicine, vol. 348, no. 2, pp. 138-150, 2003.
2. J. Cohen, J. L. Vincent, N. K. Adhikari et al. , "Sepsis: a roadmap for future research, " The Lancet Infectious Diseases, vol. 15, no. 5, pp. 581-614, 2015.
3. A. C. Ma and P. Kubes, "Platelets, neutrophils, and neutrophil extracellular traps (NETs) in sepsis, " Journal ofThrombosis and Haemostasis, vol. 6, no. 3, pp. 415-420, 2008.
4. K. Brown, S. Brain, J. Pearson, J. Edgeworth, S. Lewis, and D. Treacher, "Neutrophils in development ofmultiple organ failure in sepsis, " The Lancet, vol. 368, no. 9530, pp. 157-169, 2006.
5. G. Singer, K. Y. Stokes, and D. Neil Granger, "Reactive oxygen and nitrogen species in sepsis-induced hepatic microvascular dysfunction, " Inflammation Research, vol. 62, no. 2, pp. 155-164, 2013.
6. A. Cauwels and P. Brouckaert, "Nitrite regulation of shock, " Cardiovascular Research, vol. 89, no. 3, pp. 553-559, 2011.
7. M. Aritomi, N. Kunishima, T. Okamoto, R. Kuroki, Y. Ota, and K. Morikawa, "Atomic structure of the GCSF-receptor complex showing a new cytokine-receptor recognition scheme, " Nature, vol. 401, no. 6754, pp. 713-717, 1999.
8. K. Ishikawa, H. Tanaka, Y. Nakamori et al. , "Difference in the responses after administration of granulocyte colony-stimulating factor in septic patients with relative neutropenia, " Journal of Trauma-Injury Infection & Critical Care, vol. 48, no. 5, pp. 814-825, 2000.
9. G. S. Chatta, T. H. Price, R. C. Allen, and D. C. Dale, "Effects of in vivo recombinant methionyl human granulocyte colonystimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers, " Blood, vol. 84, no. 9, pp. 2923-2929, 1994.
10. V. Garg, H. Garg, A. Khan et al. , "Granulocyte colony-stimulating factor mobilizes CD34+ cells and improves survival of patients with acute-on-chronic liver failure, " Gastroenterology, vol. 142, no. 3, pp. 505-512. e1, 2012.
11. N. J. Taylor, A. Nishtala, G. K. ManakkatVijay et al. , "Circulating neutrophil dysfunction in acute liver failure, " Hepatology, vol. 57, no. 3, pp. 1142-1152, 2013.
12. M. A. S. Moore, "The clinical use of colony stimulating factors, " Annual Review of Immunology, vol. 9, no. 1, pp. 159-191, 1991.
13. R. Lundblad, J. M. Nesland, and K.-E. Giercksky, "Granulocyte colony-stimulating factor improves survival rate and reduces concentrations of bacteria, endotoxin, tumor necrosis factor, and endothelin-1 in fulminant intra-abdominal sepsis in rats, " Critical Care Medicine, vol. 24, no. 5, pp. 820-826, 1996.
14. P. Villa, C. L. Shaklee, C. Meazza, D. Agnello, P. Ghezzi, and G. Senaldi, "Granulocyte colony-stimulating factor and antibiotics in the prophylaxis of amurinemodel of polymicrobial peritonitis and sepsis, " Journal of Infectious Diseases, vol. 178, no. 2, pp. 471-477, 1998.
15. A. Bauhofer, A. Torossian, W. Lorenz et al. , "Dependence of positive effects of granulocyte colony-stimulating factor on the antibiotic regimen: evaluation in rats with polymicrobial peritonitis, " World Journal of Surgery, vol. 28, no. 8, pp. 834-844, 2004.
16. A. Bauhofer, I. Celik, U. Plaul, H. Wulf, and A. Torossian, "Effects of G-CSF and antibiotic prophylaxis in a 2x2 factorial design on outcome in septic rats, " Inflammation Research, vol. 53, supplement 2, pp. S126-S129, 2004.
17. L. Luo, S. Zhang, Y. Wang et al. , "Proinflammatory role of neutrophil extracellular traps in abdominal sepsis, " American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 307, no. 7, pp. L586-L596, 2014.
18. R. K. Root and D. C. Dale, "Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients, " Journal of Infectious Diseases, vol. 179, supplement 2, pp. S342-352, 1999.
19. A. Bauhofer, U. Plaul, A. Torossian et al. , "Perioperative prophylaxis with granulocyte colony-stimulating factor (G-CSF) in high-risk colorectal cancer patients for an improved recovery: a randomized, controlled trial, " Surgery, vol. 141, no. 4, pp. 501-510, 2007.
20. M. V. Relling, J. M. Boyett, J. G. Blanco et al. , "Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment, " Blood, vol. 101, no. 10, pp. 3862-3867, 2003.
21. L. Bo, F. Wang, J. Zhu, J. Li, and X. Deng, "Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a metaanalysis, " Critical Care, vol. 15, no. 1, article R58, 2011.
22. S. Nelson, S. M. Belknap, R. W. Carlson et al. , "A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia, " Journal of Infectious Diseases, vol. 178, no. 4, pp. 1075-1080, 1998.
23. R. K. Root, R. F. Lodato, W. Patrick et al. , "Multicenter, doubleblind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis, " Critical Care Medicine, vol. 31, no. 2, pp. 367-373, 2003.
24. P. Hartmann, J. Lammertink, G. Mansmann et al. , "A randomized, placebo-controlled study of the use of filgrastim in non neutropenic patients with nosocomial pneumonia, " European Journal of Medical Research, vol. 10, no. 1, pp. 29-35, 2005.
25. A. C. Cheng, D. Limmathurotsakul, W. Chierakul et al. , "A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand, " Clinical Infectious Diseases, vol. 45, no. 3, pp. 308-314, 2007.
26. D. P. Stephens, J. H. Thomas, A. Higgins et al. , "Randomized, double-blind, placebo-controlled trial of granulocyte colonystimulating factor in patients with septic shock, " Critical Care Medicine, vol. 36, no. 2, pp. 448-454, 2008.
27. H. Fang, A. Liu, J. Sun, A. Kitz, O. Dirsch, and U. Dahmen, "Granulocyte colony stimulating factor induces lipopolysaccharide (LPS) sensitization via upregulation of LPS binding protein in rat, " PLoS ONE, vol. 8, no. 2, Article ID e56654, 2013.
28. S. Hagel and F. Brunkhorst, "Sepsis, " Intensivmedizin und Notfallmedizin, vol. 48, no. 1, pp. 57-73, 2011.
29. R. P. Dellinger, M. M. Levy, A. Rhodes et al. , "Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012, " Intensive Care Medicine, vol. 39, no. 2, pp. 165-228, 2013.
30. C. Fleischmann, A. Scherag, N. K. Adhikari et al. , "Assessment of global incidence and mortality of hospital-treated sepsis-current estimates and limitations, "American Journal of Respiratory and Critical Care Medicine, 2015.
31. R. G. Holzheimer, "Antibiotic induced endotoxin release and clinical sepsis: a review, " Journal of Chemotherapy, vol. 13, supplement 2, pp. 159-172, 2001.
32. K. Buttenschoen, P. Radermacher, and H. Bracht, "Endotoxin elimination in sepsis: physiology and therapeutic application, " Langenbecks Archives of Surgery, vol. 395, no. 6, pp. 597-605, 2010.
33. Y. Hayashi, "Polymyxin B hemoperfusion (PMX-F) for severe sepsis and septic shock, " Nihon Rinsho, vol. 70, no. 2, pp. 311-314, 2012.
34. H. Huang, Y.-J. Wang, A. P. White et al. , "Salmonella expressing a T-cell epitope from Sendai virus are able to induce antiinfection immunity, " Journal of Medical Microbiology, vol. 58, no. 9, pp. 1236-1242, 2009.
35. M. J. Arana, M. G. Vallespi, G. Chinea et al. , "Inhibition of LPSresponses by synthetic peptides derived from LBP associates with the ability of the peptides to block LBP-LPS interaction, " Journal of Endotoxin Research, vol. 9, no. 5, pp. 281-291, 2003.
36. E. A. Panacek, J. C. Marshall, T. E. Albertson et al. , "Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab) 2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels, " Critical CareMedicine, vol. 32, no. 11, pp. 2173-2182, 2004.
37. T. Roger, C. Froidevaux, D. Le Roy et al. , "Protection fromlethal Gram-negative bacterial sepsis by targeting Toll-like receptor 4, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 7, pp. 2348-2352, 2009.
38. X. Wittebole, D. Castanares-Zapatero, and P. F. Laterre, "Tolllike receptor 4 modulation as a strategy to treat sepsis, " Mediators of Inflammation, vol. 2010, Article ID 568396, 9 pages, 2010.
39. M. Tidswell and S. P. LaRosa, "Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis, " Expert Review of Anti-InfectiveTherapy, vol. 9, no. 5, pp. 507-520, 2011.
40. A. Barochia, S. Solomon, X. Cui, C. Natanson, and P. Q. Eichacker, "Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies, " Expert Opinion on DrugMetabolismand Toxicology, vol. 7, no. 4, pp. 479-494, 2011.
41. W. J. Christ, O. Asano, A. L. C. Robidoux et al. , "E5531, a pure endotoxin antagonist of high potency, " Science, vol. 268, no. 5207, pp. 80-83, 1995.
42. P. S. Tobias, K. Soldau, and R. J. Ulevitch, "Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein, " The Journal of Biological Chemistry, vol. 264, no. 18, pp. 10867-10871, 1989.
43. S. M. Opal, J. E. Palardy, M. N. Marra, C. J. Fisher Jr. , B. M. McKelligon, and R. W. Scott, "Relative concentrations of endotoxinbinding proteins in body fluids during infection, " The Lancet, vol. 344, no. 8920, pp. 429-431, 1994.
44. T. R. Martin, J. C. Mathison, P. S. Tobias et al. , "Lipopolysaccharide binding protein enhances the responsiveness of alveolar macrophages to bacterial lipopolysaccharide. Implications for cytokine production in normal and injured lungs, " The Journal of Clinical Investigation, vol. 90, no. 6, pp. 2209-2219, 1992.
45. J. Fierer, M. A. Swancutt, D. Heumann, and D. Golenbock, "The role of lipopolysaccharide binding protein in resistance to Salmonella infections in mice, " The Journal of Immunology, vol. 168, no. 12, pp. 6396-6403, 2002.
46. R. M. Minter, X. Bi, G. Ben-Josef et al. , "LPS-binding protein mediates LPS-induced liver injury and mortality in the setting of biliary obstruction, " The American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 296, no. 1, pp. G45-G54, 2009.
47. R. S. Jack, X. Fan, M. Bernheiden et al. , "Lipopolysaccharidebinding protein is required to combat a murine gram-negative bacterial infection, " Nature, vol. 389, no. 6652, pp. 742-745, 1997.
48. J. Hellman and H. S. Warren, "Antiendotoxin strategies, " InfectiousDisease Clinics ofNorth America, vol. 13, no. 2, pp. 371-386, 1999.
49. F. Pene, E. Courtine, F. Ouaaz et al. , "Toll-like receptors 2 and 4 contribute to sepsis-induced depletion of spleen dendritic cells, " Infection and Immunity, vol. 77, no. 12, pp. 5651-5658, 2009.
50. S. Knapp, A. F. de Vos, S. Florquin, D. T. Golenbock, and T. van Der Poll, "Lipopolysaccharide binding protein is an essential component of the innate immune response to Escherichia coli peritonitis in mice, " Infection and Immunity, vol. 71, no. 12, pp. 6747-6753, 2003.
51. D. Le Roy, F. Di Padova, R. Tees et al. , "Monoclonal antibodies to murine lipopolysaccharide (LPS)-binding protein (LBP) protect mice from lethal endotoxemia by blocking either the binding of LPS to LBP or the presentation of LPS/LBP complexes to CD14, " The Journal of Immunology, vol. 162, no. 12, pp. 7454-7460, 1999.
52. Y. Liu, B. Ni, J.-D. Ren et al. , "Cyclic limulus anti-lipopolysaccharide (LPS) factor-derived peptide CLP-19 antagonizes LPS function by blocking binding to LPS binding protein, " Biological and Pharmaceutical Bulletin, vol. 34, no. 11, pp. 1678-1683, 2011.
53. A. Liu, S. Weiss, H. Fang et al. , "Lipopolysaccharide-binding protein (LBP) blockade augments the protective effect of granulocyte colony-stimulating factor (G-CSF) in a rat sepsismodel, " Shock, vol. 43, no. 5, pp. 497-503, 2015.
54. K. K. Yang, B. G. Dorner, U. Merkel et al. , "Neutrophil influx in response to a peritoneal infection with Salmonella is delayed in lipopolysaccharide-binding protein or CD14-deficient mice, " Journal of Immunology, vol. 169, no. 8, pp. 4475-4480, 2002.
55. T. Hartung, S. Von Aulock, C. Schneider, and E. Faist, "How to leverage an endogenous immune defense mechanism: the example of granulocyte colony-stimulating factor, " Critical Care Medicine, vol. 31, no. 1, supplement, pp. S65-S75, 2003.
56. H. Tanaka, M. Nishino, Y. Nakamori et al. , "Granulocyte colonystimulating factor (G-CSF) stiffens leukocytes but attenuates inflammatory response without lung injury in septic patients, " Journal of Trauma-Injury Infection & Critical Care, vol. 51, no. 6, pp. 1110-1116, 2001.